Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I Study of ICP-332 in Healthy Subjects
Sponsor: InnoCare Pharma Inc.
Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2024-07-23
Completion Date
2024-12-25
Last Updated
2024-08-02
Healthy Volunteers
Yes
Conditions
Interventions
ICP-332 Tablets
Eligible patients will receive ICP-332 tablets orally as per the protocol
ICP-332 Placebo Tablets
Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Locations (1)
Pharmaron CPC Inc.
Baltimore, Maryland, United States